Evidence map›Paper›PMID 28469400›Full record

ArticleBiomarker insights2017

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue.

Jessica Kristof, Kellen Sakrison, Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A Beckman, Daniel Freeman, Cindy Spittle, Wenqin Feng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker insights, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jessica KristofClinical Assay Development, MolecularMD, Portland, OR, USA.
Kellen SakrisonClinical Assay Development, MolecularMD, Portland, OR, USA.
Xiaoping JinBiostatistics and Data Management, Daiichi Sankyo Pharma Development, Edison, NJ, USA.
Kenji NakamaruTranslational Medicine and Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Matthias SchneiderPreclinical and Pharmacology, U3 Pharma GmbH, Martinsried, Germany.
Robert A BeckmanDepartments of Oncology and of Biostatistics, Bioinformatics & Biomathematics, Georgetown Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Georgetown University, Washington, DC, USA.
Daniel FreemanMedImmune, Gaithersburg, MD, USA.
Cindy SpittleClinical Assay Development, MolecularMD, Portland, OR, USA.
Wenqin FengTranslational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ, USA.
Daiichi Sankyo (United States) · USARUP Laboratories (United States) · USDaiichi-Sankyo (Japan) · JPGeorgetown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In preclinical studies, heregulin (

Indexed as

heregulinnon/small cell lung cancerReal-time reverse-transcription polymerase chain reaction (RT-qPCR)validation

Identifiers

PMID28469400
PMCPMC5391987
OpenAlexW2599100903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.